1	Racial and Sociodemographic Disparities in Blindness Associated with Primary Angle Closure
2	Glaucoma in the United States: An IRIS [®] Registry Analysis
3	
4	Sona N. Shah, MD ¹ ; Sarah Zhou, BS ¹ ; Carina Sanvicente, MD ² ; Bruce Burkemper, PhD, MPH ¹ ; Galo
5	Apolo, MS ¹ ; Charles Li, BS ³ ; Siying Li, MS ³ ; Lynn Liu, MS ³ ; Flora Lum, MD ³ ; Sasan Moghimi, MD ⁴ ;
6	and Benjamin Xu, MD, PhD ¹
7	
8	1. Roski Eye Institute, Department of Ophthalmology, University of Southern California, Los Angeles,
9	CA
10	2. Harvey & Bernice Jones Eye Institute, University of Arkansas for Medical Sciences, Little Rock, AK
11	3. American Academy of Ophthalmology, San Francisco, CA
12	4. Hamilton Glaucoma Center, Shiley Eye Institute, Department of Ophthalmology, University of
13	California, San Diego, La Jolla, CA
14	
15	Corresponding Author: Benjamin Xu, Department of Ophthalmology, Keck School of Medicine at the
16	University of Southern California, 1450 San Pablo Street, 4th Floor, Suite 4700, Los Angeles, CA 90033
17	Phone number: 323-442-6780; Fax number: 323-442-6412
18	E-mail: <u>benjamin.xu@med.usc.edu</u>
19	
20	Financial Support: This work was supported by grants K23 EY029763 from the National Eye Institute,
21	National Institute of Health, Bethesda, Maryland; an IRIS Registry Initiative Award from the American
22	Glaucoma Society; and an unrestricted grant to the Department of Ophthalmology from Research to
23	Prevent Blindness, New York, NY.
24	Conflict of Interest: No conflicting relationship exists for any author
25	Short Title: Disparities in Blindness with Primary Angle Closure Glaucoma
26	Key Words: Primary angle closure glaucoma, angle closure, blindness, healthcare disparities

1

27 Abstract

- 28 **Purpose:** To assess the prevalence and risk factors of blindness among patients newly diagnosed with
- 29 primary angle closure glaucoma (PACG) in the United States (US).
- 30 Design: Retrospective cross-sectional study of patients from the American Academy of Ophthalmology
- 31 IRIS[®] (Intelligent Research in Sight) Registry.

32 **Participants:** Patients in the IRIS[®] Registry between the years 2015 to 2019 with a new diagnosis of

33 PACG and visual acuity (VA) data on or within 90 days prior to the date of diagnosis.

34 Methods: Eligible patients were aged 18 years and older and: (1) were observable in the database at least

35 24 months prior to the index date of PACG diagnosis; (2) had no history of intraocular pressure (IOP)

36 lowering drops, laser peripheral iridotomy (LPI), cataract surgery, or a diagnosis of pseudophakia unless

37 preceded by a diagnosis of anatomical narrow angle (ANA); and (3) had no history of glaucoma surgery.

38 Multivariable logistic regression models were developed to assess risk factors of blindness.

39 **Main Outcome Measures:** Any (one or both eyes) or bilateral (both eyes) blindness (VA \leq 20/200) at 40 first diagnosis of PACG.

Results: 43,901 patients with PACG in the IRIS[®] Registry met inclusion criteria. Overall prevalence of 41 42 any and bilateral blindness were 11.5% and 1.8%, respectively. Black and Hispanic patients were at 43 higher risk of any (OR=1.42 and 1.21, respectively; p<0.001) and bilateral (OR=2.04 and 1.53, 44 respectively; p<0.001) blindness compared to non-Hispanic White patients adjusted for ocular 45 comorbidities, including cataracts. Other factors associated with any blindness included age <50 or >80 46 years, male sex, Medicaid or Medicare insurance category, and Southern or Western practice region 47 (ORs>1.28; $p \le 0.01$). Diagnosis of ANA prior to diagnosis of PACG was protective against any (OR=0.56; p<0.001) and bilateral (OR=0.61; p<0.001) blindness. 48

49 Conclusions: Blindness affects 1 out of 9 patients with newly diagnosed PACG in the IRIS[®] Registry;
50 Black and Hispanic patients and Medicaid and Medicare recipients are significantly more vulnerable.
51 These findings highlight the severe ocular morbidity associated with PACG and the need for increased
52 disease awareness and improved detection methods.

53 Introduction

54 Primary angle closure glaucoma (PACG) is a visually devastating disease and leading cause of irreversible blindness worldwide.¹⁻³ The current global prevalence of PACG is approximately 23 million, 55 56 although this number is projected to rise to approximately 32 million by 2040 due to the aging of the world's population.¹ Any rise in the prevalence of PACG is problematic due to high rates of blindness 57 associated with the disease; it is estimated that blindness affects 27.0% of those with PACG worldwide.³ 58 59 Quality of life (QoL), defined as an individual's experience of health, comfort, happiness, and ability to enjoy day-to-day life activities, is significantly diminished by blindness, especially in bilateral cases.⁴⁻⁶ 60 61 Blindness also has a profound impact on healthcare expenditures and the global economy; the economic burden of vision loss has been estimated to be \$134.2 billion annually in the United States (US) alone.⁷ 62 63 Therefore, there exists an urgent need to better understand the burden and risk factors of blindness 64 secondary to treatable ocular diseases, such as PACG, on diverse patient populations.

65 While primary open angle closure glaucoma (POAG) is twice as common as PACG, PACG 66 confers a two-fold higher risk of blindness.³ Therefore, POAG and PACG are associated with a similar number of cases of blindness worldwide.⁸ The visually devastating nature of PACG stems from 67 68 anatomical mechanisms underlying the disease. Angle closure is characterized by contact between the peripheral iris and trabecular meshwork, which impedes outflow of aqueous humor from the eve.⁹ 69 70 Extensive angle closure can lead to complete obstruction of outflow, elevated intraocular pressure (IOP) 71 that is higher than typically observed in open angle eyes, and rapid glaucomatous damage to the optic 72 nerve. Laser and surgical treatments help alleviate angle closure, which effectively delay or prevent the onset of elevated IOP and PACG.^{10,11} Therefore, many cases of irreversible blindness associated with 73 74 PACG could be avoided if high-risk patients are identified and treated earlier in the disease course.

There are an estimated 700,000 people with PACG in the US.¹ However, the visual impact of PACG in the US is poorly studied, due in part to the low perceived impact of PACG among non-Asian individuals and the racial and ethnic diversity of the US population. In this study, we use data from the IRIS[®] Registry (Intelligent Research in Sight) to study the prevalence of blindness among patients newly

diagnosed with PACG in the US. The US has the highest total health expenditure per capita of worldwide; therefore, it is reasonable to speculate that there should be lower ocular morbidity associated with PACG in the US compared to other regions of the world.¹²⁻¹⁹ We also assess sociodemographic factors to identify populations more vulnerable to PACG-associated blindness who could benefit from increased provider awareness and improved detection methods.

- 84
- 85 Methods
- 86 <u>Data</u>

The American Academy of Ophthalmology IRIS® Registry is a comprehensive clinical registry that 87 88 includes data on approximately 441 million patient visits for over 73 million unique patients as of April 1, 2022. Available eye-level clinical data (with specified laterality in the IRIS[®] Registry) included dates of 89 90 clinical diagnoses (including PACG), visual acuity (VA), intraocular pressure (IOP), and dates of procedures including laser peripheral iridotomy (LPI) and cataract and glaucoma surgeries. Available 91 patient-level clinical data included history of IOP-lowering medications (laterality not specified in the 92 IRIS[®] Registry). Available patient-level sociodemographic data included age, race, sex, insurance 93 94 category, and practice region. Race and ethnicity, which are cultural constructs with biological contribution through genetic heritage, are combined into a single variable in the IRIS[®] Registry. This 95 96 study was approved by The University of Southern California Institutional Review Board. The study adhered to the tenets of the Declaration of Helsinki and complied with the Health Insurance Portability 97 98 and Accountability Act.

99

100 <u>Study Population Selection and Definitions</u>

Inclusion in the study population required a new diagnosis of PACG. Eligible patients with newly diagnosed PACG were identified from the IRIS[®] Registry between 2015 to 2019. Inclusion in the study population required an index diagnosis of PACG based on *International Classification of Diseases Ninth Revision* (ICD-9) or *Tenth Revision* (ICD-10) codes (Supplementary Table 1). PACG diagnoses were

analyzed on the eye level. The index date of diagnosis was defined as the date of the first visit associatedwith a PACG diagnosis.

107 Eligible patients were aged 18 years and older with newly diagnosed PACG, defined as: (1) 108 observable in the IRIS[®] Registry for at least 24 months prior to the index date of PACG diagnosis; (2) no 109 history of IOP lowering drops, LPI, cataract surgery, or a diagnosis of pseudophakia unless preceded by a 110 diagnosis of ANA (also referred to as primary angle closure without glaucoma) based on ICD or Current 111 Procedural Terminology (CPT) codes (Supplementary Table 1); (3) no history of glaucoma surgery 112 (defined as trabeculectomy, glaucoma shunt, and cyclophotocoagulation) based on CPT codes 113 (Supplementary Table 1). Criterion 1 was implemented to ensure that cases of PACG were newly 114 diagnosed, based on the standard-of-care practice of monitoring PACG patients at least once per year. 115 Criterion 2 was implemented to ensure that patients who had potentially received angle closure 116 interventions for a diagnosis of ANA rather than PACG would not be excluded from the analyses. 117 Criterion 3 was implemented to ensure that patients who had previously received glaucoma interventions 118 would not be designated as newly diagnosed PACG.

119 Visual acuity data from the index date of diagnosis were analyzed on the eye level. Blindness was 120 defined as $VA \le 20/200$ in at least one eye (any blindness) or in both eyes (bilateral blindness) on or 121 within 90 days prior to the index date of diagnosis. If multiple VAs were documented within that time 122 frame, the VA closest to the index date was utilized. Patients without VA data from at least one eye with 123 PACG on or within 90 days prior to the index date of diagnosis were excluded from the analysis. Only 124 patients with bilateral VA data were eligible for analyses on bilateral blindness.

125

126 <u>Statistical Analysis</u>

127 Continuous data were expressed as means and standard deviations. Categorical data were expressed in 128 proportions and percentages. Univariable and multivariable logistic regression analyses were performed 129 to determine odds ratios (OR) for any and bilateral blindness adjusted for ocular comorbidities (cataracts, 130 diabetic retinopathy, and macular degeneration diagnoses based on ICD codes). Variables significant at p

131 < 0.15 in univariable analysis were included in multivariable analysis. Separate multivariable models 132 were developed for any blindness, bilateral blindness, and any blindness additionally adjusted for IOP. 133 The threshold for statistical and clinical significance was set at $OR \ge 1.20$ and $p \le 0.01$ to avoid 134 interpretation of weak effects due to large sample size. All statistical analyses were performed using R 135 (The R Foundation for Statistical Computing, Vienna, Austria).

- 136
- 137 Results

A total of 223,029 unique patients with an eye-level diagnosis of PACG from 2015 to 2019 were identified in the IRIS[®] Registry (Figure 1). There were 43,901 unique patients who met criteria for newly diagnosed PACG after patients were excluded based on the lack of a minimum 24-month lookback period (116,535 patients excluded), presence of prior treatment and surgical history (48,326 patients excluded), or the absence of VA data from at least one eye with PACG on or within the 90 days prior to the index date of diagnosis (14,267 patients excluded).

144 Out of 43,901 patients with VA data for at least one eye with newly diagnosed PACG, 5,064 (11.54%) were blind in at least one eye; out of 41,904 patients with bilateral VA data, 736 (1.76%) were 145 146 blind in both eyes (Table 1). The effects of age and race on prevalence of any blindness and bilateral blindness were similar. The proportion of any and bilateral blindness were highest in patients < 40147 148 (31.02% and 9.52\%, respectively) and > 80 (18.60\% and 3.60\%, respectively) years of age; higher in 149 males (13.71% and 1.95%, respectively) compared to females (10.41% and 1.66%, respectively); and 150 higher in Black patients (14.2% and 2.93% respectively) and Hispanic patients (12.53% and 2.26%, 151 respectively) compared to non-Hispanic White patients (Tables 1 and 2).

Multivariable logistic regression analysis showed significant associations between any blindness and the following parameters (Table 3): age groups < 40 (OR = 3.54, 95% CI 2.93-4.26), 40-49 (OR = 1.41, 95% CI 1.18-1.68), and \geq 80 years (OR = 1.79, 95% CI 1.60-2.02) compared to 50-59 years; Black race (OR = 1.42, 95% CI 1.29-1.57) or Hispanic ethnicity (OR = 1.21, 95% CI 1.10-1.33) compared to non-Hispanic White race; Southern (OR = 1.34, 95% CI 1.23-1.46) or Western (OR = 1.31, 95% CI 1.19-

157 1.44) practice regions compared to the Northeast practice region; Medicaid (OR = 2.06, 95% CI 1.75-158 2.42), Medicare fee-for-service (FFS) (OR = 1.51, 95% CI 1.37-1.65), or Medicare Managed (OR = 1.28, 159 95% CI 1.13-1.46) insurance category compared to private insurance; history of cataract (OR = 1.57, 95% 160 CI 1.45-1.69) or macular degeneration (OR = 1.37, 95% CI 1.18-1.60); and PACG diagnosis without 161 prior ANA diagnosis (OR =1.78, 95% CI 1.66-1.90). Female sex (OR = 0.75, 95% CI 0.71-0.80) was 162 associated with significantly lower odds of any blindness compared to male sex.

163 Multivariable logistic regression analysis showed significant associations between bilateral 164 blindness and the following parameters (Table 4): age groups < 40 (OR = 5.58, 95% CI 3.89-8.00) and >165 80 (OR = 1.82, 95% CI 1.35-2.45) years of age compared to 50-59 years; Black race (OR = 2.04, 95% CI 166 1.64-2.53) or Hispanic ethnicity (OR = 1.53, 95% CI 1.23-1.90) compared to non-Hispanic White race; 167 Southern (OR = 1.41, 95% CI 1.14-1.74) practice region compared to the Northeast practice region; 168 Medicaid (OR = 3.85, 95% CI 2.71-5.48), Medicare fee-for-service (FFS) (OR = 2.70, 95% CI 2.07-169 3.51), or Medicare Managed (OR = 1.84, 95% CI 1.27-2.65) insurance categories compared to private 170 insurance; history of cataract (OR = 1.48, 95% CI 1.23-1.78) or macular degeneration (OR = 1.74, 95% 171 CI 1.25-2.40); and PACG diagnosis without prior ANA diagnosis (OR = 1.64, 95% CI 1.39-1.94) (Table 172 4). Age group 70-79 years (OR = 0.52, 95% CI 0.35-0.71) was significantly associated with lower odds of bilateral blindness compared to 50-59 years. 173

The multivariable logistic regression model for any blindness was additionally adjusted for IOP (Supplementary Table 2). Results were similar to those from the multivariable model for any blindness without adjustment for IOP (Table 3); however, association with Western practice region was no longer significant, and diabetic retinopathy (OR = 2.00, 95% CI 1.65-2.42) was significantly associated with higher odds of any blindness (Supplementary Table 2).

179

180 Discussion

In this study, we used data from the IRIS[®] Registry to assess the prevalence and risk factors of blindness
among patients with newly diagnosed PACG in the US. The overall prevalence of any and bilateral

183 blindness among patients with newly diagnosed PACG were 11.5% and 1.8%, respectively. There were 184 significant racial disparities in the prevalence of PACG-associated blindness; Black and Hispanic patients 185 had 42% and 21% higher odds of blindness compared to non-Hispanic White patients. Other 186 sociodemographic factors associated with blindness included age < 40 or > 80 years, male sex, Medicaid 187 or Medicare insurance, and Southern or Western practice region. Diagnosis of ANA prior to diagnosis of 188 PACG was protective against any and bilateral blindness. These findings highlight deficiencies in current 189 practice patterns related to PACG; specifically, the need for increased disease awareness among eye care 190 providers and development of more effective clinical methods to detect patients at high-risk of PACG.

191 The overall prevalence of any blindness among patients with newly diagnosed PACG in the US 192 was relatively high regardless of age, sex, and race. It is well-established that PACG is a visually devastating disease: a meta-analysis of 23 population-based studies estimated the prevalence of PACG-193 associated blindness to be 27.0%.³ However, blindness rates vary widely by geographic region.^{3,12,14-16,20,21} 194 195 For example, studies conducted in more developed countries and/or urban regions reported lower 196 prevalence of blindness: 5.3% in the Tajimi Study, 6.1% in the Kumejima Study, and 10.2% in the Singapore Chinese Eye Study.^{14,16,20} Conversely, studies conducted in China consistently reported higher 197 198 prevalence of blindness regardless of the degree of urbanization: 25.0% in the Beijing Eye Study, 25.5% in the Handan Eye Study, 42.9% in the Liwan Eye Study, and 71.7% in the Yunnan Minority Eye 199 Study.^{12,15,21,22} However, prior to our study, there was sparse information on PACG-associated visual 200 201 morbidity among racial and ethnic populations in the US. Our findings provide compelling evidence that 202 the US does not have substantially lower rates of PACG-associated blindness compared to other 203 developed countries despite having higher healthcare expenditure per capita.

There are significant racial and ethnic differences in the prevalence of PACG-associated blindness; in this study, Black (14.20%, 1 per 7.0 cases) and Hispanic patients (12.53%, 1 per 8.0 cases) were disproportionately affected compared to non-Hispanic White (11.19%, 1 per 8.9 cases) and Asian patients (8.86%, 1 per 11.2 cases). These racial disparities were magnified for bilateral blindness: 1 in 34.5 Black patients (2.93%) and 1 in 43.5 Hispanic patients (2.26%) were bilaterally blind compared to 1

209 in 64.5 non-Hispanic White patients (1.55%) and 1 in 81.3 Asian patients (1.23%). Furthermore, these 210 disparities appear to be independent of IOP and ocular comorbidities, including cataracts. There are 211 several likely explanations for these observations. First, it is widely recognized that PACG is most common among Asian individuals, with around half of global cases occurring in China.^{8,16-18,23,24} In 212 213 contrast, there is sparse information about the prevalence of PACG among other races and ethnicities. The 214 Beaver Dam Eye Study reported low prevalence of PACG among Black and non-Hispanic White 215 participants, finding only two definite cases of narrow-angle glaucoma in 4,926 participants; however, it is unclear how often angle assessments were performed.²⁵ Therefore, provider-level biases about racial or 216 217 ethnic differences in PACG prevalence may contribute to greater vigilance about angle closure among 218 Asian individuals. However, such biases should not lead to differences in angle closure detection between 219 Black and non-Hispanic White patients, as both racial groups are thought to have low PACG prevalence. 220 Second, there may be racial and ethnic differences in ocular biometry, such as anterior chamber depth, 221 that could influence the likelihood of eye care providers performing gonioscopy to detect angle closure prior to development of glaucomatous damage.^{26,27} Finally, differences in utilization of and access to eye 222 care services between racial and ethnic groups could influence visual outcomes.^{28,29} Overall, these 223 224 findings support the need for additional research on racial and ethnic differences in anatomical 225 mechanisms of angle closure and the development of more effective clinical methods to risk-stratify 226 patients for PACG.

227 Older age over 80 years and younger age under 40 years were both risk factors for any and 228 bilateral blindness compared to age 50-59 years. While age is a well-established risk factor for PACG, PACG tends to be rare in younger populations.^{12,13,30,31} We speculate that the anatomical mechanisms 229 underlying PACG differ between younger and older patients affected by blindness.³¹⁻³³ In older patients, 230 cataract formation contributes to increased lens thickness and likely worsening of pupillary block and 231 other lens-related mechanisms.³⁴ In younger patients, PACG may be attributed to other mechanisms of 232 233 angle closure, such as severe forms of plateau iris syndrome, nanopthalmos, or other developmental or 234 congenital anomalies, that contribute to more advanced disease and profound vision loss at first

diagnosis.^{31,33} Although PACG is rare in younger patients, more effective detection and treatment of
PACG in this subpopulation would have a longer-lasting benefit for patients and healthcare systems.

237 Patient sex, practice region, and insurance category were identified as additional risk factors for 238 blindness. Male sex was identified as a risk factor for any blindness, which could be attributed to lower utilization of medical care among men, leading to later disease detection.³⁵ Patients seeking care in 239 240 Western and Southern regions compared to the Northeast region were at higher risk for any and bilateral 241 blindness, which could be attributed to differences in regional practices and screening methods. There 242 may also be regional differences in access to care and density of evecare providers that we could not account for due to limitations of IRIS® Registry data.³⁶ Finally, patients with Medicaid, Medicare FFS, or 243 244 Medicare were at higher risk for any blindness compared to patients with private insurance. We speculate that insurance serves as a proxy for socioeconomic status in our analyses, as the IRIS[®] Registry does not 245 246 contain data on patient income, net worth, education level, or health literacy. Therefore, the increased risk 247 of blindness associated with certain insurance products may reflect the effects of these confounding 248 factors.

249 The diagnosis of ANA prior to the diagnosis of PACG was protective against any and bilateral 250 blindness, suggesting that earlier detection of ANA is associated with more favorable clinical outcomes. 251 Gonioscopy is the current clinical standard for detecting angle closure and distinguishing POAG from PACG.^{2,37-39} However, gonioscopy has a number of limitations, such as being expertise-dependent and 252 potentially time-consuming or uncomfortable, that contribute to its underutilization.³⁸ In addition, around 253 three-quarters of patients with newly diagnosed PACG in the US do not have a prior diagnosis of ANA.³⁹ 254 255 While there are automated non-contact methods utilizing anterior segment OCT (AS-OCT) imaging and 256 artificial intelligence (AI) to detect gonioscopic angle closure, these methods are not widely available for clinical use.⁴⁰⁻⁴² Our findings on PACG-associated blindness highlight the need to further develop and 257 258 implement more convenient clinical tools to detect patients at risk for PACG.

259 Our study has several limitations. First, our analyses relied on clinical diagnoses of PACG 260 provided by a large number of practicing ophthalmologists, some of which may not comply with the

formal definition of PACG proposed for epidemiological studies.⁴³ It is feasible that some cases of PACG 261 were misclassified cases of ANA (angle closure without glaucoma) or POAG; this would likely lower our 262 263 estimates of PACG-associated blindness. However, we intentionally avoided applying additional criteria 264 to narrow the definition of PACG, which could introduce systematic biases toward higher estimates of 265 PACG-associated blindness. Second, we did not have access to visual field data. Therefore, we could not 266 adopt a more comprehensive definition of blindness that includes <20 degrees of visual field; this would 267 likely lead to further underestimation of the visual impact of PACG. Third, the duration of our lookback period to establish PACG cases as newly diagnosed was at minimum two years. As the IRIS[®] Registry 268 269 was recently launched in 2014, this substantially reduced our study sample size, which could limit the 270 generalizability of our findings. Fourth, while we accounted for the three most common ocular co-271 morbidities (cataracts, age-related macular degeneration, and diabetic retinopathy) in our analyses, it is 272 possible that other ocular diseases contributed to blindness. However, we believe that confounding is 273 unlikely given that PACG has no known associations with systemic or other ocular diseases aside from 274 cataracts. Finally, we cannot rule out that underlying racial and ethnic disparities in ocular health amplified racial and ethnic differences in the prevalence of blindness in our study.⁴⁴ 275

276 Our findings support that PACG is a visually devastating disease, even in the US. Historical 277 epidemiological studies on PACG have shaped perception that the burden of PACG falls primarily on 278 Asian patients, yet Black and Hispanic patients have significantly higher risk of PACG-associated 279 blindness. These findings highlight the importance of renewed efforts to increase awareness about PACG 280 and associated ocular morbidity. They also call into question the utilization of healthcare resources and 281 the effectiveness of current practice patterns for detecting and managing patients at risk for PACG. We 282 propose the development of more convenient and precise clinical tools for detecting and evaluating 283 patients with angle closure, especially given the projected rise in PACG prevalence worldwide. Finally, this study demonstrates the importance and benefit of the IRIS[®] Registry for studying the broader impact 284 285 of ocular diseases within the US and mitigating their damaging effects by identifying and raising 286 awareness about vulnerable patient populations.

287

288 **Table and Figure Captions**

- Figure 1. Attrition diagram of patients with diagnosis of PACG.
- Table 1. Proportion of blindness in newly diagnosed PACG cases stratified by sex and age.
- Table 2. Proportion of blindness in newly diagnosed PACG cases stratified by race and age.
- Table 3. Univariable and multivariable analysis of risk factors for any blindness in PACG.
- Table 4. Univariable and multivariable analysis of risk factors for bilateral blindness in PACG.
- Supplementary Table 1. Diagnosis, procedure, and treatment codes used in the study.
- 295 Supplementary Table 2. Univariable and multivariable analysis of risk factors for any blindness in PACG
- additionally adjusted for IOP.

297

298 Acknowledgements

This work was supported by grants K23 EY029763 from the National Eye Institute, National Institute of Health, Bethesda, Maryland; an IRIS Registry Initiative Award from the American Glaucoma Society; and an unrestricted grant to the Department of Ophthalmology from Research to Prevent Blindness, New York, NY.

303

304 References

- Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of
 glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-
- analysis. *Ophthalmology*. Nov 2014;121(11):2081-90. doi:10.1016/j.ophtha.2014.05.013
- 2. Congdon N, Wang F, Tielsch JM. Issues in the epidemiology and population-based screening
- 309 of primary angle-closure glaucoma. *Surv Ophthalmol.* 1992 May-Jun 1992;36(6):411-23.
- doi:10.1016/s0039-6257(05)80022-0

311	3.	George R,	Panda S, Vijaya	L. Blindness in	glaucoma: primar	y open-	angle glau	coma ve	ersus
312		primary	angle-closure	glaucoma-a	meta-analysis.	Eye	(Lond).	Oct	13
313		2021;doi:1	0.1038/s41433-0	21-01802-9					

- 4. Gupta V, Srinivasan G, Mei SS, Gazzard G, Sihota R, Kapoor KS. Utility values among
- glaucoma patients: an impact on the quality of life. *Br J Ophthalmol*. Oct 2005;89(10):1241-
- 316 4. doi:10.1136/bjo.2005.068858
- Ejiakor I, Achigbu E, Onyia O, Edema O, Florence UN. Impact of Visual Impairment and
 Blindness on Quality of Life of Patients in Owerri, Imo State, Nigeria. *Middle East Afr J Ophthalmol.* 2019 Jul-Sep 2019;26(3):127-132. doi:10.4103/meajo.MEAJO 256 18

320 6. Frick KD, Gower EW, Kempen JH, Wolff JL. Economic impact of visual impairment and

- blindness in the United States. Arch Ophthalmol. Apr 2007;125(4):544-50.
 doi:10.1001/archopht.125.4.544
- 7. Rein DB, Wittenborn JS, Zhang P, et al. The Economic Burden of Vision Loss and Blindness
 in the United States. *Ophthalmology*. Sep 21 2021;doi:10.1016/j.ophtha.2021.09.010
- 8. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and

2020. Br J Ophthalmol. Mar 2006;90(3):262-7. doi:10.1136/bjo.2005.081224

- 9. Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a
 review. *JAMA*. May 14 2014;311(18):1901-11. doi:10.1001/jama.2014.3192
- 329 10. Azuara-Blanco A, Burr J, Ramsay C, et al. Effectiveness of early lens extraction for the
- treatment of primary angle-closure glaucoma (EAGLE): a randomised controlled trial.
- 331 *Lancet*. Oct 01 2016;388(10052):1389-1397. doi:10.1016/S0140-6736(16)30956-4
- 11. Jiang Y, Friedman DS, He M, Huang S, Kong X, Foster PJ. Design and methodology of a
 randomized controlled trial of laser iridotomy for the prevention of angle closure in southern

- China: the Zhongshan angle Closure Prevention trial. *Ophthalmic Epidemiol*. Oct 2010;17(5):321-32. doi:10.3109/09286586.2010.508353
- 12. Wang L, Huang W, Huang S, et al. Ten-year incidence of primary angle closure in elderly
- Chinese: the Liwan Eye Study. Br J Ophthalmol. 03 2019;103(3):355-360.
- doi:10.1136/bjophthalmol-2017-311808
- 13. Foster PJ, Oen FT, Machin D, et al. The prevalence of glaucoma in Chinese residents of
 Singapore: a cross-sectional population survey of the Tanjong Pagar district. *Arch Ophthalmol.* Aug 2000;118(8):1105-11. doi:10.1001/archopht.118.8.1105
- 14. Baskaran M, Foo RC, Cheng CY, et al. The Prevalence and Types of Glaucoma in an Urban
 Chinese Population: The Singapore Chinese Eye Study. *JAMA Ophthalmol*. Aug
 2015;133(8):874-80. doi:10.1001/jamaophthalmol.2015.1110
- 15. Liang Y, Friedman DS, Zhou Q, et al. Prevalence and characteristics of primary angleclosure diseases in a rural adult Chinese population: the Handan Eye Study. *Invest Ophthalmol Vis Sci.* Nov 07 2011;52(12):8672-9. doi:10.1167/iovs.11-7480
- 348 16. Yamamoto T, Iwase A, Araie M, et al. The Tajimi Study report 2: prevalence of primary
 angle closure and secondary glaucoma in a Japanese population. *Ophthalmology*. Oct
 2005;112(10):1661-9. doi:10.1016/j.ophtha.2005.05.012
- 17. Vijaya L, George R, Arvind H, et al. Prevalence of primary angle-closure disease in an urban
 south Indian population and comparison with a rural population. The Chennai Glaucoma
 Study. *Ophthalmology*. Apr 2008;115(4):655-660.e1. doi:10.1016/j.ophtha.2007.05.034
- 18. Dandona L, Dandona R, Mandal P, et al. Angle-closure glaucoma in an urban population in
 southern India. The Andhra Pradesh eye disease study. *Ophthalmology*. Sep
 2000;107(9):1710-6. doi:10.1016/s0161-6420(00)00274-8

357	19. Papanicolas I, Woskie LR, Jha AK. Health Care Spending in the United States and Other
358	High-Income Countries. JAMA. Mar 13 2018;319(10):1024-1039.
359	doi:10.1001/jama.2018.1150
360	20. Yamamoto S, Sawaguchi S, Iwase A, et al. Primary open-angle glaucoma in a population
361	associated with high prevalence of primary angle-closure glaucoma: the Kumejima Study.
362	Ophthalmology. Aug 2014;121(8):1558-65. doi:10.1016/j.ophtha.2014.03.003
363	21. Wang YX, Xu L, Yang H, Jonas JB. Prevalence of glaucoma in North China: the Beijing Eye
364	Study. Am J Ophthalmol. Dec 2010;150(6):917-24. doi:10.1016/j.ajo.2010.06.037
365	22. Wang Y, Cun Q, Li J, et al. Prevalence, ethnic differences and risk factors of primary angle-
366	closure glaucoma in a multiethnic Chinese adult population: the Yunnan Minority Eye Study.
367	Br J Ophthalmol. Dec 21 2021;doi:10.1136/bjophthalmol-2021-320241
368	23. Arkell SM, Lightman DA, Sommer A, Taylor HR, Korshin OM, Tielsch JM. The prevalence
369	of glaucoma among Eskimos of northwest Alaska. Arch Ophthalmol. Apr 1987;105(4):482-
370	5. doi:10.1001/archopht.1987.01060040052031
371	24. Foster PJ, Johnson GJ. Glaucoma in China: how big is the problem? Br J Ophthalmol. Nov
372	2001;85(11):1277-82. doi:10.1136/bjo.85.11.1277
373	25. Klein BE, Klein R, Sponsel WE, et al. Prevalence of glaucoma. The Beaver Dam Eye Study.
374	Ophthalmology. Oct 1992;99(10):1499-504. doi:10.1016/s0161-6420(92)31774-9
375	26. Oh YG, Minelli S, Spaeth GL, Steinman WC. The anterior chamber angle is different in
376	different racial groups: a gonioscopic study. Eye (Lond). 1994;8 (Pt 1):104-8.
377	doi:10.1038/eye.1994.20

- 378 27. Thompson AC, Vu DM, Cowan LA, Asrani S. Risk Factors Associated with Missed
- 379 Diagnoses of Narrow Angles by the Van Herick Technique. *Ophthalmol Glaucoma*. 2018

380 Sep - Oct 2018;1(2):108-114. doi:10.1016/j.ogla.2018.08.002

- 28. Shi Q, Zhao Y, Fonseca V, Krousel-Wood M, Shi L. Racial disparity of eye examinations
- among the U.S. working-age population with diabetes: 2002-2009. *Diabetes Care*.
- 383 2014;37(5):1321-8. doi:10.2337/dc13-1038
- 29. Halawa OA, Kolli A, Oh G, et al. Racial and Socioeconomic Differences in Eye Care
 Utilization among Medicare Beneficiaries with Glaucoma. *Ophthalmology*. 04
 2022;129(4):397-405. doi:10.1016/j.ophtha.2021.09.022
- 30. Seah SK, Foster PJ, Chew PT, et al. Incidence of acute primary angle-closure glaucoma in
 Singapore. An island-wide survey. *Arch Ophthalmol.* Nov 1997;115(11):1436-40.
 doi:10.1001/archopht.1997.01100160606014
- 390 31. Gao F, Wang J, Chen J, Wang X, Chen Y, Sun X. Etiologies and clinical characteristics of
- 391 young patients with angle-closure glaucoma: a 15-year single-center retrospective study.
- 392 *Graefes Arch Clin Exp Ophthalmol.* Aug 2021;259(8):2379-2387. doi:10.1007/s00417-021-
- 393 05172-6
- 394 32. Chang BM, Liebmann JM, Ritch R. Angle closure in younger patients. *Trans Am*395 *Ophthalmol Soc.* 2002;100:201-12; discussion 212-4.
- 33. Stieger R, Kniestedt C, Sutter F, Bachmann LM, Stuermer J. Prevalence of plateau iris
 syndrome in young patients with recurrent angle closure. *Clin Exp Ophthalmol.* Jul
- 398 2007;35(5):409-13. doi:10.1111/j.1442-9071.2007.01510.x

399	34. Nongpiur	ME, He	M, Amera	usinghe N, et	t al. Lens vault, thic	kness, an	d position in Chinese
400	subjects	with	angle	closure.	Ophthalmology.	Mar	2011;118(3):474-9.
401	doi:10.101	6/j.ophth	na.2010.07	.025			

- 402 35. Benoit SR, Swenor B, Geiss LS, Gregg EW, Saaddine JB. Eye Care Utilization Among
- 403 Insured People With Diabetes in the U.S., 2010-2014. *Diabetes Care*. 03 2019;42(3):427-
- 404 433. doi:10.2337/dc18-0828
- 36. Cassard SD, Quigley HA, Gower EW, Friedman DS, Ramulu PY, Jampel HD. Regional
 variations and trends in the prevalence of diagnosed glaucoma in the Medicare population.

407 *Ophthalmology*. Jul 2012;119(7):1342-51. doi:10.1016/j.ophtha.2012.01.032

- 408 37. Park SB, Sung KR, Kang SY, Jo JW, Lee KS, Kook MS. Assessment of narrow angles by
- gonioscopy, Van Herick method and anterior segment optical coherence tomography. *Jpn J Ophthalmol.* Jul 2011;55(4):343-350. doi:10.1007/s10384-011-0036-0
- 38. Varma DK, Simpson SM, Rai AS, Ahmed IIK. Undetected angle closure in patients with a
 diagnosis of open-angle glaucoma. *Can J Ophthalmol.* Aug 2017;52(4):373-378.
 doi:10.1016/j.jcjo.2016.12.010
- 414 39. Apolo G, Bohner A, Pardeshi A, et al. Racial and Sociodemographic Disparities in the
 415 Detection of Narrow Angles Prior to Primary Angle Closure Glaucoma in the United States.
 416 *Ophthalmol Glaucoma*. Jan 24 2022;doi:10.1016/j.ogla.2022.01.001
- 40. Xu BY, Chiang M, Chaudhary S, Kulkarni S, Pardeshi AA, Varma R. Deep Learning
 Classifiers for Automated Detection of Gonioscopic Angle Closure Based on Anterior
 Segment OCT Images. *Am J Ophthalmol.* 12 2019;208:273-280.
 doi:10.1016/j.ajo.2019.08.004

421	41. Pardeshi AA, Song AE, Lazkani N, Xie X, Huang A, Xu BY. Intradevice Repeatability and
422	Interdevice Agreement of Ocular Biometric Measurements: A Comparison of Two Swept-
423	Source Anterior Segment OCT Devices. Transl Vis Sci Technol. 08 2020;9(9):14.
424	doi:10.1167/tvst.9.9.14
425	42. Shen A, Chiang M, Pardeshi AA, McKean-Cowdin R, Varma R, Xu BY. Anterior segment
426	biometric measurements explain misclassifications by a deep learning classifier for detecting
427	gonioscopic angle closure. Br J Ophthalmol. Oct 06 2021;doi:10.1136/bjophthalmol-2021-
428	319058
429	43. Foster PJ, Buhrmann R, Quigley HA, Johnson GJ. The definition and classification of
430	glaucoma in prevalence surveys. Br J Ophthalmol. Feb 2002;86(2):238-42.
431	doi:10.1136/bjo.86.2.238
432	44. Sommer A, Tielsch JM, Katz J, et al. Racial differences in the cause-specific prevalence of
433	blindness in east Baltimore. N Engl J Med. Nov 14 1991;325(20):1412-7.
434	doi:10.1056/NEJM199111143252004
435	

Figure 1. Attrition diagram of patients with newly diagnosed PACG in the IRIS® (Intelligent Research in Sight) Registry.




 Table 1. Proportion of blindness in newly diagnosed PACG cases stratified by sex and age.

					AN	Y* BLINDN	ESS					
		Male			Female			Unknowr	l		Overall	
Age	N (PACG)	N (Blind)	%	N (PACG)	N (Blind)	%	N (PACG)	N (Blind)	%	N (PACG)	N (Blind)	%
<40	299	104	34.78%	416	119	28.61%	7	1	14.29%	722	224	31.02%
40-49	508	94	18.50%	1063	106	9.97%	6	0	0.00%	1577	200	12.68%
50-59	1784	247	13.85%	3962	265	6.69%	26	4	15.38%	5772	516	8.94%
60-69	4058	434	10.69%	8636	658	7.62%	75	8	10.67%	12769	1100	8.61%
70-79	5066	594	11.73%	9693	888	9.16%	91	15	16.48%	14850	1497	10.08%
80+	2874	527	18.34%	5291	990	18.71%	46	10	21.74%	8211	1527	18.60%
Overall	14589	2000	13.71%	29061	3026	10.41%	251	38	15.14%	43901	5064	11.54%

BILATERAL BLINDNESS

		Male			Female		Unknown Overall					
Age	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%
<40	272	32	11.76%	384	31	8.07%	6	0	0.00%	662	63	9.52%
40-49	464	14	3.02%	1009	18	1.78%	5	0	0.00%	1478	32	2.17%
50-59	1691	30	1.77%	3798	41	1.08%	24	0	0.00%	5513	71	1.29%
60-69	3861	63	1.63%	8301	81	0.98%	71	3	4.23%	12233	147	1.20%
70-79	4855	52	1.07%	9293	91	0.98%	87	0	0.00%	14235	143	1.00%
80+	2722	80	2.94%	5016	200	3.99%	45	0	0.00%	7783	280	3.60%
Overall	13865	271	1.95%	27801	462	1.66%	238	3	1.26%	41904	736	1.76%

PACG = primary angle closure glaucoma; N and n = number of patients.

* Any refers to uni- or bilateral blindness.

Table 2.	Proportion of blindness in	n newly diagnosed PACG cases	stratified by race and age.
----------	----------------------------	------------------------------	-----------------------------

								А	NY* BLIN	DNESS								
	Non-I	Hispanic V	Vhite		Black			Hispanic			Asian			Unknown			Overall	
Age	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%
<40	393	119	30.28%	88	34	38.64%	117	41	35.04%	27	4	14.81%	97	26	26.80%	722	224	31.02%
40-49	880	104	11.82%	156	35	22.44%	229	37	16.16%	90	1	1.11%	222	23	10.36%	1577	200	12.68%
50-59	3267	259	7.93%	670	77	11.49%	809	87	10.75%	334	29	8.68%	692	64	9.25%	5772	516	8.94%
60-69	7584	639	8.43%	1471	155	10.54%	1689	144	8.53%	704	48	6.82%	1321	114	8.63%	12769	1100	8.61%
70-79	9343	883	9.45%	1422	193	13.57%	1926	216	11.21%	750	65	8.67%	1409	140	9.94%	14850	1497	10.08%
80+	5610	1027	18.31%	645	138	21.40%	840	178	21.19%	353	53	15.01%	763	131	17.17%	8211	1527	18.60%
Overall	27077	3031	11.19%	4452	632	14.20%	5610	703	12.53%	2258	200	8.86%	4504	498	11.06%	43901	5064	11.54%

BILATERAL BLINDNESS

	Non-l	Hispanic W	hite		Black			Hispanic			Asian			Unknown			Overall	
Age	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%	N (PACG)	n (Blind)	%
<40	367	34	9.26%	80	12	15.00%	112	14	12.50%	23	0	0.00%	80	3	3.75%	662	63	9.52%
40-49	825	13	1.58%	141	8	5.67%	214	10	4.67%	85	1	1.18%	213	0	0.00%	1478	32	2.17%
50-59	3146	41	1.30%	615	12	1.95%	769	12	1.56%	321	1	0.31%	662	5	0.76%	5513	71	1.29%
60-69	7331	71	0.97%	1376	26	1.89%	1615	26	1.61%	662	5	0.76%	1249	19	1.52%	12233	147	1.20%
70-79	9001	64	0.71%	1349	35	2.59%	1844	25	1.36%	693	7	1.01%	1348	12	0.89%	14235	143	1.00%
80+	5333	180	3.38%	606	29	4.79%	795	34	4.28%	331	12	3.63%	718	25	3.48%	7783	280	3.60%
Overall	26003	403	1.55%	4167	122	2.93%	5349	121	2.26%	2115	26	1.23%	4270	64	0.10%	41904	736	1.76%

PACG = primary angle closure glaucoma; N and n = number of patients.

* Any refers to uni- or bilateral blindness.

		Any* Blindness (+)	Any Blindness (-)	Univariable An	alysis	Multivariable A	nalysis
		N (%)	N (%)	OR (CI)	P value	OR (CI)	P value
Total # PACG patients.	3,901	5,064 (11.54%)	38,837 (88.46%)				
Age [years]	0,701						
50-59		516 (8.94%)	5,256 (91.06%)	REF		REF	
<40		224 (31.02%)	498 (68.98%)	4.58 (3.82-5.50)	< 0.001	3.54 (2.93-4.26)	<0.001
40-49		200 (12.68%)	1,377 (87.32%)	1.48 (1.24-1.76)	< 0.001	1.41 (1.18-1.68)	<0.001
60-69		1,100 (8.61%)	11,669 (91.39%)	0.96 (0.86-1.07)	0.467	0.84 (0.75-0.95)	0.004
70-79		1,497 (10.08%)	13,353 (89.92%)	1.14 (1.03-1.27)	0.013	0.92 (0.82-1.04)	0.169
80+		1,527 (18.60%)	6,684 (81.40%)	2.33 (2.10-2.59)	< 0.001	1.79 (1.60-2.02)	<0.001
Sex							
Male		2,000 (15.64%)	12,589 (84.36%)	REF		REF	
Female		3,026 (10.41%)	26,035 (89.59%)	0.73 (0.69-0.78)	< 0.001	0.75 (0.71-0.80)	<0.001
Not Reported		38 (15.14%)	213 (84.86%)	1.12 (0.79-1.59)	0.514	1.12 (0.78-1.60)	0.530
Race							
Caucasian		3,031 (11.19%)	24,046 (88.81%)	REF		REF	
Asian		200 (8.86%)	2,058 (91.14%)	0.77 (0.66-0.90)	0.001	0.82 (0.70-0.96)	0.014
Black or African Ame	rican	632 (14.20%)	3,820 (85.80%)	1.31 (1.20-1.44)	< 0.001	1.42 (1.29-1.57)	<0.001
Hispanic		703 (12.53%)	4,907 (87.47%)	1.14 (1.04-1.24)	0.004	1.21 (1.10-1.33)	<0.001
Unknown		498 (11.06%)	4,006 (88.94%)	0.99 (0.89-1.09)	0.787	1.00 (0.90-1.11)	0.967
Practice Region							
Northeast		995 (9.41%)	9,578 (90.59%)	REF		REF	
Midwest		1,138 (11.52%)	8,741 (88.48%)	1.25 (1.15-1.37)	< 0.001	1.05 (0.96-1.16)	0.306
South		1,847 (12.86%)	12,520 (87.14%)	1.42 (1.31-1.54)	< 0.001	1.34 (1.23-1.46)	<0.001
West		845 (11.87%)	6,275 (88.13%)	1.30 (1.18-1.43)	< 0.001	1.31 (1.19-1.44)	<0.001
Unknown		239 (12.18%)	1,723 (87.82%)	1.34 (1.15-1.55)	< 0.001	1.23 (1.06-1.44)	0.007
Insurance Category							
Private		828 (8.43%)	8,998 (91.57%)	REF		REF	
Government		63 (9.18%)	623 (90.82%)	1.10 (0.84-1.44)	0.491	1.12 (0.85-1.48)	0.407
Medicaid		249 (17.29%)	1,191 (82.71%)	2.27 (1.95-2.65)	< 0.001	2.06 (1.75-2.42)	<0.001
Medicare FFS		3,250 (12.76%)	22,224 (87.24%)	1.59 (1.47-1.72)	< 0.001	1.51 (1.37-1.65)	<0.001
Medicare Managed		445 (10.62%)	3,747 (89.38%)	1.29 (1.14-1.46)	< 0.001	1.28 (1.13-1.46)	<0.001
Military		29 (12.29%)	207 (87.71%)	1.52 (1.03-2.26)	0.037	1.35 (0.90-2.03)	0.141
Unknown/Missing		200 (9.77%)	1,847 (90.23%)	1.18 (1.00-1.38)	0.049	1.12 (0.95-1.33)	0.168
Ocular comorbidities							
Cataract	No	3,746 (10.51%)	31,899 (89.49%)	REF		REF	
	Yes	1,318 (15.96%)	6,938 (84.04%)	1.63 (1.52-1.74)	< 0.001	1.57 (1.45-1.69)	<0.001
Diabetic Retinopathy	No	4,728 (11.28%)	37,173 (88.72%)	REF		REF	
^ *	Yes	336 (16.80%)	1,664 (83.20%)	1.58 (1.40-1.78)	< 0.001	1.04 (0.89-1.22)	0.626
Macular Degeneration	No	4,659 (11.16%)	37,096 (88.84%)	REF		REF	
-	Yes	405 (18.87%)	1,741 (81.13%)	1.83 (1.64-2.05)	< 0.001	1.37 (1.18-1.60)	<0.001
ANA prior to PACG		-				,	
-	Yes	1,406 (8.33%)	15,476 (91.67%)	REF		REF	
	No	3,658 (13.54%)	23,361 (86.46%)	1.72 (1.62-1.84)	< 0.001	1.78 (1.66-1.90)	<0.001

Table 3. Univariable and multivariable analysis of risk factors for any* blindness in PACG.

ANA = anatomic narrow angle; CI = confidence interval; N = number of patients; OR = odds ratio; FFS = fee-for-service; PACG = primary angle closure glaucoma. * Any refers to uni- or bilateral blindness.

Statistically significant multivariable p-values and odds ratios with $OR \ge 1.20$ and $p \le 0.01$ are bolded.

		Bilateral Blindness (+)	Bilateral Blindness (-)	Univariable An	alysis	Multivariable A	nalysis	
	-	N (%)	N (%)	OR (CI)	P value	OR (CI)	P valu	
Total # PACG patients:	1,904	736 (1.76%)	41,168 (98.24%)					
Age [years]	1,704							
50-59		71 (1.29%)	5,442 (98.71%)	REF		REF		
<40		63 (9.52%)	599 (90.48%)	8.06 (5.68-11.44)	< 0.001	5.58 (3.89-8.00)	<0.001	
40-49		32 (2.17%)	1,446 (97.83%)	1.70 (1.11-2.59)	0.014	1.63 (1.07-2.50)	0.024	
60-69		147 (1.20%)	12,086 (98.80%)	0.93 (0.70-1.24)	0.630	0.71 (0.52-0.96)	0.024	
70-79		143 (1.00%)	14,092 (99.00%)	0.78 (0.58-1.04)	0.085	0.52 (0.38-0.71)	<0.024	
80+		280 (3.60%)	7,503 (96.40%)	2.86 (2.20-3.72)	< 0.001	1.82 (1.35-2.45)	<0.00	
Sex		200 (3.0070)	7,303 (90.4070)	2.00 (2.20-3.72)	<0.001	1.02 (1.55-2.45)	\0.00	
Male		271 (1.95%)	13,594 (98.05%)	REF		REF		
Female		462 (1.66%)	27,339 (98.34%)	0.85 (0.73-0.99)	0.032	0.89 (0.76-1.04)	0.134	
Not Reported		3 (1.26%)	235 (98.74%)	0.64 (0.20-2.01)	0.446	0.57 (0.18-1.83)	0.134	
Race		5 (1.2070)	200 (70.7 170)	3.01 (0.20 2.01)	0.110	0.57 (0.10 1.05)	0.544	
Caucasian		403 (1.55%)	25,600 (98.45%)	REF		REF		
Asian		26 (1.23%)	2,089 (98.77%)	0.79 (0.53-1.18)	0.249	0.93 (0.62-1.41)	0.742	
Black or African Amer	rican	122 (2.93 %)	4,045 (97.07%)	1.92 (1.56-2.35)	< 0.001	2.04 (1.64-2.53)	<0.00	
Hispanic	icuii	121 (2.26%)	5,228 (97.74%)	1.47 (1.20 - 1.81)	<0.001	1.53 (1.23-1.90)	<0.00	
Unknown		64 (1.50%)	4,206 (98.50%)	0.967 (.074-1.26)	0.802	1.00 (0.76-1.32)	0.990	
Practice Region		01 (1.50%)	1,200 (70.5070)	0.507 (.071 1.20)	0.002	1.00 (0.70 1.52)	0.770	
Northeast		133 (1.32%)	9,916 (98.68%)	REF		REF		
Midwest		160 (1.67%)	9,408 (98.33%)	1.27 (1.01-1.60)	0.045	0.952 (0.74-1.22)	0.701	
South		290 (2.12%)	13,379 (97.88%)	1.62 (1.31-1.99)	< 0.001	1.41 (1.14-1.74)	0.001	
West		111 (1.64%)	6,647 (98.36%)	1.25 (0.97-1.61)	0.091	1.21 (0.93-1.57)	0.157	
Unknown		42 (2.26%)	1,818 (97.74%)	1.72 (1.21-2.45)	0.002	1.49 (1.05-2.13)	0.027	
Insurance Category		.2 (2.2070)	1,010 () /// //0)	11/2 (1121 2110)	0.002	1119 (1100 2110)	01027	
Private		83 (0.88%)	9,348 (99.12%)	REF		REF		
Government		4 (0.61%)	648 (99.39%)	0.70 (0.25-1.90)	0.479	0.69 (0.25-1.91)	0.479	
Medicaid		60 (4.45%)	1,287 (95.55%)	5.25 (3.75-7.36)	< 0.001	3.85 (2.71-5.48)	<0.00	
Medicare FFS		499 (2.05%)	23,810 (97.95%)	2.36 (1.87-2.98)	< 0.001	2.70 (2.07-3.51)	<0.00	
Medicare Managed		53 (1.33%)	3,930 (98.67%)	1.52 (1.07-2.15)	0.018	1.84 (1.27-2.65)	0.001	
Military		6 (2.71%)	215 (97.29%)	3.14 (1.36-7.28)	0.008	2.71 (1.15-6.36)	0.022	
Unknown/Missing		31 (1.58%)	1,930 (98.42%)	1.81 (1.19-2.74)	0.005	1.82 (1.19-2.78)	0.005	
Ocular comorbidities		(-,((> =)			0.000	
Cataract	No	529 (1.55%)	33,580 (98.45%)	REF		REF		
	Yes	207 (2.66%)	7,588 (97.34%)	1.73 (1.47-2.04)	< 0.001	1.48 (1.23-1.78)	<0.00	
Diabetic Retinopathy	No	667 (1.67%)	39,299 (98.33%)	REF		REF		
·····J	Yes	69 (3.56%)	1,869 (96.44%)	2.18 (1.69-2.80)	< 0.001	1.28 (0.91-1.81)	0.153	
Macular Degeneration	No	656 (1.65%)	39,186 (98.35%)	REF		REF		
	Yes	80 (3.88%)	1,982 (96.12%)	2.41 (1.90-3.05)	< 0.001	1.74 (1.25-2.40)	0.001	
ANA prior to PACG			,	(
	Yes	204 (1.26%)	16,024 (98.74%)	REF		REF		
	No	532 (2.07%)	25,144 (97.93%)	1.66 (1.41-1.96)	< 0.001	1.64 (1.39-1.94)	<0.00	

Table 4. Univariable and multivariable analysis of risk factors for bilateral blindness in PACG.

ANA = anatomic narrow angle; CI = confidence interval; N = number of patients; OR = odds ratio; FFS = fee-for-service; PACG = primary angle closure glaucoma. Statistically significant multivariable p-values and odds ratios with OR \ge 1.20 and $p \le$ 0.01 are bolded.